Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia.
Hematology/Oncology Fellowship Program, University of Washington, Seattle, WA;
Anna B
AB
Halpern
Public Health Sciences Division and Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA;
Gary H
GH
Lyman
Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Pediatrics, and Department of Microbiology and Immunology, Weill Cornell Medical Center, New York, NY;
Thomas J
TJ
Walsh
Department of Infectious Diseases, Division of Internal Medicine, University of Texas MD Anderson Cancer Center, Houston, TX; and.
Dimitrios P
DP
Kontoyiannis
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Medicine, Division of Hematology, and Department of Epidemiology, University of Washington, Seattle, WA.
Roland B
http://orcid.org/0000-0002-9268-3341
RB
Walter
D000935:Antifungal Agents / Q000627:therapeutic use*; D006801:Humans; D016867:Immunocompromised Host; D015470:Leukemia, Myeloid, Acute / Q000150:complications*; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000209:etiology / Q000276:immunology / Q000517:prevention & control*
D000935:Antifungal Agents